Here’s Why Aurinia Pharmaceuticals Stock Jumped Higher Today
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were up 14% at 3:35 p.m. EST on Tuesday as investors anticipated the release of clinical trial data for the biotech's lead drug voclosporin.
In October, Aurinia said the last patient had a final study visit in the Aurora phase 3 clinical trial testing voclosporin plus Roche's CellCept in patients with lupus nephritis. Aurinia indicated that results would be reported by the end of the year.
With a little over a month left before the calendar changes over, biotech investors are jumping in ahead of the binary event.
Source Fool.com
